Piper Sandler Adjusts Price Target on AbbVie to $196 From $190
HC Wainwright Adjusts Price Target on United Therapeutics to $400 From $300, Maintains Buy Rating
BioMarin Pharmaceutical Price Target Maintained With a $89.00/Share by Canaccord Genuity
Biomarin Pharmaceutical Analyst Ratings
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Cuts Target Price to $89
H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $400
United Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Healthequity (HQY), Community Health (CYH) and Gilead Sciences (GILD)
Barclays Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $76
Oppenheimer Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
Oppenheimer Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $215
Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen
Vertex Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,200
Gilead Sciences (GILD) Receives a Buy From TD Cowen
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85